The big pharmaceutical companies are in trouble. Patents are expiring, innovation is slowing and the next blockbuster is not in sight. "Only a transformation of the business model will position Large Pharma for future growth," say Deloitte analysts. This paper outlines the industry's limited opportunities and urges the companies to build on their commercial capabilities while the window of opportunity is still open.
Published in Brief: